Danaher Corp. (DHR – Q1FY20) – Cytiva acquisition to boost growth in FY21.

in on July 21, 2020

Danaher Corporation announced it completed the sale of its label-free biomolecular characterization, chromatography hardware and resins, microcarriers and particle validation standards, single use tangential flow filtration systems, and stainless steel hollow fiber tangential flow filtration systems businesses to Sartorius AG for approximately $825 million. The combined revenue of the businesses, which were part of Danaher’s Life Sciences segment, was approximately $170 million in 2019. The cpmpany  sold these businesses in order to obtain regulatory approval for its acquisition of the GE Biopharma business, now called Cytiva. The closing of the Sartorius AG agreement was conditioned upon Danaher closing its acquisition of Cytiva, which was completed.

Executive Summary

Financial Statements

– Income Statement and Forecast
– Balance Sheet
– Cash Flow
– Q1FY20 Results– Overview
– Q1FY20 – Segment Performance
– FY20 – Guidance and Conclusion
– GAAP to Non-GAAP reconciliation

Historical Performance

– Key Ratios
– Profitability Ratios, Asset Turnover Ratio, Growth Ratio
– Per Share Items and Key Ratios
– Key Balance Sheet and Cash Flow Items
– P/E Band

Product Performance and Key Developments

– Ownership
– Competitors
– Key Developments

Valuation and Consensus Performance

– Relative Valuation
– Analyst Recommendations

Market Price Performance

CrispIdea Coverage Chart

Release Information

  • Released

    July 21, 2020

  • Last Updated

    July 21, 2020